Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-Senl-h19 CAR T cells

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-Senl-h19 CAR T cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Senl-h19 CAR T cells
Senl-h19 CAR-T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search